MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
157.34
-1.28
-0.81%
After Hours: 157.34 0 0.00% 19:30 08/18 EDT
OPEN
157.96
PREV CLOSE
158.62
HIGH
160.00
LOW
156.81
VOLUME
471.65K
TURNOVER
--
52 WEEK HIGH
160.00
52 WEEK LOW
54.50
MARKET CAP
10.18B
P/E (TTM)
151.71
1D
5D
1M
3M
1Y
5Y
1D
J&J's New Growth Powerhouses: Immunology and Neuroscience
NASDAQ · 14h ago
Protagonist Therapeutics Is Maintained at Outperform by BMO Capital
Dow Jones · 1d ago
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178
Benzinga · 1d ago
Protagonist Therapeutics price target raised to $178 from $112 at BMO Capital
TipRanks · 1d ago
Corcept, Revolution Medicines lead ten large-cap healthcare stocks surging in 2026
Seeking Alpha · 1d ago
Weekly Report: what happened at PTGX last week (0810-0814)?
Weekly Report · 1d ago
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Benzinga · 5d ago
J.P. Morgan Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)
TipRanks · 5d ago
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.